Roivant Sciences Ltd.
ROIV
$27.85
-$0.25-0.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -256.98% | 50.68% | -334.38% | -36.63% | -96.68% |
| Total Depreciation and Amortization | -64.44% | -51.91% | -46.41% | -40.81% | -22.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 118.23% | -64.07% | 124.86% | -167.69% | 93.89% |
| Change in Net Operating Assets | 117.65% | -31.38% | 45.93% | 116.13% | -350.55% |
| Cash from Operations | 5.20% | 30.41% | -5.99% | -59.11% | 1.52% |
| Capital Expenditure | 370.11% | -687.95% | -318.13% | -132.38% | -414.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 9,419.15% | -97.05% |
| Other Investing Activities | -65.32% | 103.77% | -- | 12,275.68% | -- |
| Cash from Investing | -75.89% | 103.66% | -112,409.43% | 15,405.11% | -91.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -540.71% |
| Issuance of Common Stock | 323.96% | 850.30% | 1,223.51% | 254.88% | 216.57% |
| Repurchase of Common Stock | 90.53% | 94.34% | 67.05% | -958.59% | -7,505.64% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 220.24% | 157.38% | 71.58% | -443.01% | -215.34% |
| Foreign Exchange rate Adjustments | 140.30% | -76.09% | 129.74% | 42.81% | -135.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 988.44% | 99.96% | -72.32% | 636.25% | -100.52% |